Lady smiling at home holding home screening kit

Driving Increased Colorectal Cancer Screening: Addressing a Substantial Unmet Need

Pfizer established an agreement with Exact Sciences Corporation, a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, to co-promote Cologuard®, the first and only noninvasive stool DNA screening test for colorectal cancer approved by the U.S. Food and Drug Administration (FDA). Pfizer has combined its first-rate sales, marketing, media, account management and medical teams with Exact Sciences' sales, medical and industry-leading diagnostic capabilities to battle this serious public health issue. Colorectal cancer, regarded as the most preventable yet least prevented form of cancer, causes 50,000 deaths each year in the U.S. alone, underscoring the significant unmet patient need to increase screenings. Nine out of 10 people survive more than five years when colorectal cancer is diagnosed at an early stage, yet less than two-thirds of people are up-to-date with recommended screenings.

Cologuard box
Go back

Explore Our Innovation